A feasibility study of carboplatin desensitization protocol in ovarian cancer

A feasibility study of carboplatin desensitization protocol in ovarian cancer - A feasibility study of carboplatin desensitization protocol in ovarian cancer

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016603

Enrollment

Registered

2015-02-23

Start date

2015-02-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ovarian cancer

Interventions

Carboplatin desensitization every 3 or 4 weeks

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1)Patients need a histologically or cytologically diagnosis of ovarian malignancy(including peritoneal cancer and fallopian tube cancer). 2)Platinum-free interval > 6 monthes. 3)They are 20 years or older. 4)They have Eastern Cooperative Oncology Group(ECOG)performance status of 0-2. 5)They have experienced hypersensitive reaction with carboplatin. 6)They have adequate organ functions. 7)Written informed consent by the patient.

Exclusion criteria

Exclusion criteria: 1)Continuous medication with antihistamine. 2)Active systemic infections to be treated. 3)Active multiple primart cancer (prognosis < 12 monthes) 4)With severe complications. 5)Women during pregnancy, possible pregnancy, or breast-feeding. 6)Psychiatric disease. 7)Continuous systemic steroid treatment. 8)doctor's decision not to be registered to this study.

Design outcomes

Primary

Measure	Time frame
Completion rate of desensitization protocol	—

Secondary

Measure	Time frame
Efficacy Progression free survival Overall survival	—

Countries

Japan

Contacts

Public ContactKoji Matsumoto

Hyogo Cancer Center Division of Medical Oncology

kojmatsu@hp.pref.hyogo.jp078-929-1151

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026